[Future developments in the therapy of acute ST segment elevation myocardial infarction]

Area of Science:

• Cardiology
• Vascular Biology
• Regenerative Medicine

Context:

• Acute myocardial infarction (AMI) treatment has evolved over decades.
• Identification of thrombotic coronary occlusion as the cause led to thrombolysis.
• Advancements in thrombolytic and antithrombotic therapies improved outcomes.

Purpose:

• To review the evolution of AMI treatment.
• To discuss the shift from thrombolysis to percutaneous coronary intervention (PCI).
• To outline future therapeutic goals and potential approaches for AMI.

Summary:

• PCI, supported by antiplatelet agents like clopidogrel and GP IIb/IIIa antagonists, has become a primary reperfusion strategy.
• Future research focuses on increasing patient access to care, reducing reperfusion time, myocardial protection, and functional reconstitution of necrotic tissue.
• Potential strategies include public awareness, combined therapies, pharmacological interventions, and progenitor cell therapy.

Impact:

• Improved clinical outcomes and reduced mortality rates for AMI patients.
• PCI has become a cornerstone of AMI treatment due to its safety and efficacy.
• Future advancements aim to further enhance recovery and reduce long-term damage from AMI.